pmc logo image
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
Juan J Gomez-Reino, Loreto Carmona,
Arthritis Res Ther. 2006; 8(1): R29. Published online 2006 January 6. doi: 10.1186/ar1881
PMCID:
PMC1526564
Abstract Full Text PDF–196K
 Is Cited by the Following 19 Articles in this Archive:
Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study
Sarika Ogale, Elena Hitraya, Henry J Henk
BMC Musculoskelet Disord. 2011; 12: 204. Published online 2011 September 19. doi: 10.1186/1471-2474-12-204
PMCID:
PMC3184114
Abstract Full Text PDF–326K Supplementary Material
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Shunsuke Mori, Yukitaka Ueki
Mod Rheumatol. 2011 December; 21(6): 628–636. Published online 2011 May 1. doi: 10.1007/s10165-011-0460-5
PMCID:
PMC3236821
Abstract Full Text PDF–237K
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
Regina Rendas-Baum, Gene V Wallenstein, Tamas Koncz, Mark Kosinski, Min Yang, John Bradley, Samuel H Zwillich
Arthritis Res Ther. 2011; 13(1): R25. Published online 2011 February 16. doi: 10.1186/ar3249
PMCID:
PMC3241369
Abstract Full Text PDF–677K Supplementary Material
Safety and clinical efficacy of golimumab in the treatment of arthritides
Ismail Simsek, Yusuf Yazici
Drug Healthc Patient Saf. 2010; 2: 169–180. Published online 2010 September 28. doi: 10.2147/DHPS.S6187
PMCID:
PMC3108699
Abstract Full Text PDF–197K
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
Martin Rudwaleit, Filip Van den Bosch, Martina Kron, Sonja Kary, Hartmut Kupper
Arthritis Res Ther. 2010; 12(3): R117. Published online 2010 June 16. doi: 10.1186/ar3054
PMCID:
PMC2911911
Abstract Full Text PDF–791K
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S Smolen, Robert Landewé, Ferdinand C Breedveld, Maxime Dougados, Paul Emery, Cecile Gaujoux-Viala, Simone Gorter, Rachel Knevel, Jackie Nam, Monika Schoels, Daniel Aletaha, Maya Buch, Laure Gossec, Tom Huizinga, Johannes W J W Bijlsma, Gerd Burmester, Bernard Combe, Maurizio Cutolo, Cem Gabay, Juan Gomez-Reino, Marios Kouloumas, Tore K Kvien, Emilio Martin-Mola, Iain McInnes, Karel Pavelka, Piet van Riel, Marieke Scholte, David L Scott, Tuulikki Sokka, Guido Valesini, Ronald van Vollenhoven, Kevin L Winthrop, John Wong, Angela Zink, Désirée van der Heijde
Ann Rheum Dis. 2010 June 1; 69(6): 964–975. Published online 2010 June 1. doi: 10.1136/ard.2009.126532
PMCID:
PMC2935329
Abstract Full Text PDF–1.7M
Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
Amr A. Saad, Darren M. Ashcroft, Kath D. Watson, Deborah P. M. Symmons, Peter R. Noyce, Kimme L. Hyrich
Rheumatology (Oxford) 2010 April; 49(4): 697–705. Published online 2010 January 7. doi: 10.1093/rheumatology/kep423
PMCID:
PMC2838413
Abstract Full Text PDF–84K
The impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study
Tessa Sanderson, Michael Calnan, Marianne Morris, Pam Richards, Sarah Hewlett
Musculoskeletal Care. Author manuscript; available in PMC 2010 June 17.
Published in final edited form as: Musculoskeletal Care. 2009 September; 7(3): 194–209. doi: 10.1002/msc.149
PMCID:
PMC2886965
Abstract Full Text PDF–153K
DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists
Federico Navarro-Sarabia, Dolores Ruiz-Montesinos, Blanca Hernandez, Victoria Navarro-Compán, Sara Marsal, Mireia Barcelo, Eva Perez-Pampín, Juan J Gómez-Reino
BMC Musculoskelet Disord. 2009; 10: 91. Published online 2009 July 23. doi: 10.1186/1471-2474-10-91
PMCID:
PMC2724400
Abstract Full Text PDF–230K
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
A Finckh, A Ciurea, L Brulhart, B Möller, U A Walker, D Courvoisier, D Kyburz, J Dudler, C Gabay, on the behalf of the doctors of the Swiss Clinical Quality Management Programme for Rheumatoid Arthritis
Ann Rheum Dis. 2010 February; 69(2): 387–393. Published online 2009 May 15. doi: 10.1136/ard.2008.105064
PMCID:
PMC2800201
Abstract Full Text PDF–592K
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Amr A Saad, Darren M Ashcroft, Kath D Watson, Kimme L Hyrich, Peter R Noyce, Deborah PM Symmons, the British Society for Rheumatology Biologics Register
Arthritis Res Ther. 2009; 11(2): R52. Published online 2009 April 8. doi: 10.1186/ar2670
PMCID:
PMC2688203
Abstract Full Text PDF–134K
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Andrea Rubbert-Roth, Axel Finckh
Arthritis Res Ther. 2009; 11(Suppl 1): S1. Published online 2009 April 6. doi: 10.1186/ar2666
PMCID:
PMC2669237
Abstract Full Text PDF–446K
Sustained Remission After Combination Therapy with Rituximab and Etanercept in Two Patients with Rheumatoid Arthritis After TNF Failure: Case Report
Martin Feuchtenberger, Christian Kneitz, Petra Roll, Stefan Kleinert, Hans-Peter Tony
Open Rheumatol J. 2009; 3: 9–13. Published online 2009 February 9. doi: 10.2174/1874312900903010009
PMCID:
PMC2684711
Abstract Full Text PDF–53K
Predictors of Discontinuation of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
SANDEEP K. AGARWAL, ROBERTA J. GLASS, NANCY A. SHADICK, JONATHAN S. COBLYN, RONALD J. ANDERSON, NANCY E. MAHER, MICHAEL E. WEINBLATT, DANIEL H. SOLOMON
J Rheumatol. Author manuscript; available in PMC 2009 October 2.
Published in final edited form as: J Rheumatol. 2008 September; 35(9): 1737–1744. Published online 2008 July 15.
PMCID:
PMC2756035
Abstract Full Text PDF–307K
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug
K. L. Hyrich, M. Lunt, W. G. Dixon, K. D. Watson, D. P. M. Symmons, on behalf of the BSR Biologics Register
Rheumatology (Oxford) 2008 July; 47(7): 1000–1005. Published online 2008 April 17. doi: 10.1093/rheumatology/ken127
PMCID:
PMC2430221
Abstract Full Text PDF–106K
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
Arie E. van der Bijl, Ferdinand C. Breedveld, Christian E. Antoni, Joachim R. Kalden, Sonja Kary, Gerd R. Burmester, Christina Beckmann, Kristina Unnebrink, Hartmut Kupper
Clin Rheumatol. 2008 August; 27(8): 1021–1028. Published online 2008 March 19. doi: 10.1007/s10067-008-0866-4
PMCID:
PMC2468311
Abstract Full Text PDF–182K
Infliximab (Remicade) in the treatment of psoriatic arthritis
Philip Mease
Ther Clin Risk Manag. 2006 December; 2(4): 389–400. Published online 2006 December.
PMCID:
PMC1936360
Abstract Full Text PDF–212K
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
Lars Erik Kristensen, Tore Saxne, Jan-Åke Nilsson, Pierre Geborek
Arthritis Res Ther. 2006; 8(6): R174. Published online 2006 November 22. doi: 10.1186/ar2084
PMCID:
PMC1794519
Abstract Full Text PDF–351K
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Christine Beeton, Heike Wulff, Nathan E. Standifer, Philippe Azam, Katherine M. Mullen, Michael W. Pennington, Aaron Kolski-Andreaco, Eric Wei, Alexandra Grino, Debra R. Counts, Ping H. Wang, Christine J. LeeHealey, Brian S. Andrews, Ananthakrishnan Sankaranarayanan, Daniel Homerick, Werner W. Roeck, Jamshid Tehranzadeh, Kimber L. Stanhope, Pavel Zimin, Peter J. Havel, Stephen Griffey, Hans-Guenther Knaus, Gerald T. Nepom, George A. Gutman, Peter A. Calabresi, K. George Chandy
Proc Natl Acad Sci U S A. 2006 November 14; 103(46): 17414–17419. Published online 2006 November 6. doi: 10.1073/pnas.0605136103
PMCID:
PMC1859943
Abstract Full Text PDF–720K Supplementary Material
You are here: NCBI > Literature > PubMed Central
Write to the Help Desk